Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.
about
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewCurrent Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with ThiazolidinedionesHypaphorine Attenuates Lipopolysaccharide-Induced Endothelial Inflammation via Regulation of TLR4 and PPAR-γ Dependent on PI3K/Akt/mTOR Signal Pathway.Anti-angiogenic treatment strategies for the therapy of endometriosis.2-methoxyestradiol induces vasodilation by stimulating NO release via PPARγ/PI3K/Akt pathway.Activation of nuclear factor erythroid 2-related factor 2 coordinates dimethylarginine dimethylaminohydrolase/PPAR-γ/endothelial nitric oxide synthase pathways that enhance nitric oxide generation in human glomerular endothelial cells.The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1α pathway.Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinedionesImpaired dopamine D1 receptor-mediated vasorelaxation of mesenteric arteries in obese Zucker rats.Examining the role of insulin in the regulation of cardiovascular health.Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic ImplicationsThe Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.PPARγ activation inhibits cerebral arteriogenesis in the hypoperfused rat brain.Fish oil blunted nicotine-induced vascular endothelial abnormalities possibly via activation of PPARγ-eNOS-NO signals.Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation.
P2860
Q24561401-E8862233-0AB4-4874-B0B1-19639BC72203Q26745533-B37A1ADA-1187-487B-9820-4B0633AA44ABQ33624829-A1B64F55-C817-4CC8-A049-D2564EA945F7Q34283036-CD7AD365-9E95-4E14-B3E0-95F89CCB50F2Q35154584-55D0DFF7-D6B7-4D2A-A2C7-B57A7CF50871Q35175624-9DFC4916-D73B-483A-B24A-A6F6512B59F7Q36220903-7A32F67E-913C-4BB7-907C-ED37FAFB4CB8Q36701580-18175C82-05B4-4313-9C08-026A34174D90Q37609291-B87AA991-A3CE-452E-A1EF-59055791968BQ38069198-75862E75-3F69-49C1-BC8F-65EF98BD4721Q38546589-0341A946-D46F-485A-8A4D-74ACB6ADB622Q39185669-4A5A0C03-734C-41EE-95EB-3322540E03F0Q40143324-1B909085-475C-48F6-AA29-658310BB455BQ46755110-DC88BC6E-83E6-40C3-BBE5-5EDE80618849Q47697799-49AB1CBD-EA32-439E-8172-763DE23EDF60Q53141326-832C3C98-8155-4191-A4B5-49A82D2948FF
P2860
Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@en
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@nl
type
label
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@en
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@nl
prefLabel
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@en
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@nl
P2860
P1476
Submaximal PPARγ activation an ...... t of cardiovascular disorders.
@en
P2093
Sonam Kathuria
P2860
P304
P356
10.1111/J.1476-5381.2012.01938.X
P407
P577
2012-08-01T00:00:00Z